SCHEMBL13837396

SCHEMBL13837396

CCCCCCCCCCCCCCCCCCOc1cc(COc2cc(C[O])cc(OCc3cc(OCCCCCCCCCCCCCCCCCC)c(OCCCCCCCCCCCCCCCCCC)c(OCCCCCCCCCCCCCCCCCC)c3)c2OCc2cc(OCCCCCCCCCCCCCCCCCC)c(OCCCCCCCCCCCCCCCCCC)c(OCCCCCCCCCCCCCCCCCC)c2)cc(OCCCCCCCCCCCCCCCCCC)c1OCCCCCCCCCCCCCCCCCC

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
THRA P10827 3/20 0.40
THRB P10828 3/20 0.40
SRC P12931 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13837398 0.92 THRA (0.45) THRATHRB
SCHEMBL13837100 0.90 PLA2G2A (0.42) THRATHRB
SCHEMBL13837298 0.85 THRA (0.40) THRATHRBSRC
SCHEMBL13837179 0.85 SRC (0.39) THRATHRBSRC
SCHEMBL13837181 0.85 SRC (0.39) THRATHRBSRC
SCHEMBL19549634 0.85 SRC (0.39) THRATHRBSRC
SCHEMBL452254 0.85 THRA (0.40) THRATHRBSRC
SCHEMBL19549568 0.84 THRA (0.38) THRATHRBSRC
SCHEMBL13837233 0.83 PLA2G2A (0.55) THRATHRB
SCHEMBL19549597 0.81 SMPD1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2711370-B1 METHOD FOR PRODUCING OLIGONUCLEOTIDES AJINOMOTO KK (JP) 2018-01-03 EP claimed
US-9790497-B2 Morpholino oligonucleotide manufacturing method AJINOMOTO CO., INC. (JP) 2017-10-17 US claimed
EP-3015467-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD Ajinomoto Co., Inc. (JP) 2016-05-04 EP claimed
US-20160076033-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD AJINOMOTO CO., INC. (JP) 2016-03-17 US claimed
US-9029528-B2 Solution-based method of making oligonucleotides via phosphoramidite coupling AJINOMOTO CO., INC. (JP) 2015-05-12 US claimed
EP-2711370-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE Ajinomoto Co., Inc. (JP) 2014-03-26 EP claimed
US-20120296074-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2012-11-22 US claimed
US-20240018180-A1 OLIGONUCLEOTIDE PRODUCTION METHOD AJINOMOTO CO., INC. (JP) 2024-01-18 US disclosed
EP-4293035-A1 OLIGONUCLEOTIDE PRODUCTION METHOD AJINOMOTO CO., INC. (JP) 2023-12-20 EP disclosed
EP-3950698-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATE SITE AJINOMOTO CO., INC. (JP) 2022-02-09 EP disclosed
US-20220010348-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATED SITE AJINOMOTO CO., INC. (JP) 2022-01-13 US disclosed
EP-3925964-A1 PRODUCTION METHOD FOR OLIGONUCLEOTIDES AJINOMOTO CO., INC. (JP) 2021-12-22 EP disclosed
US-20210371450-A1 PRODUCTION METHOD FOR OLIGONUCLEOTIDES AJINOMOTO CO., INC. (JP) 2021-12-02 US disclosed
EP-3208277-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD AJINOMOTO CO., INC. (JP) 2017-08-23 EP disclosed
US-20170218361-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD AJINOMOTO CO., INC. (JP) 2017-08-03 US disclosed
EP-3015467-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD Ajinomoto Co., Inc. (JP) 2016-05-04 EP disclosed
US-20160076033-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD AJINOMOTO CO., INC. (JP) 2016-03-17 US disclosed
US-9029528-B2 Solution-based method of making oligonucleotides via phosphoramidite coupling AJINOMOTO CO., INC. (JP) 2015-05-12 US disclosed
EP-2711370-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE Ajinomoto Co., Inc. (JP) 2014-03-26 EP disclosed
US-20120296074-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2012-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220010348-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATED SITE RNGTT, NUDT1, ADAR THRA 2901/4885THRB 3922/4885SRC 2932/4885
US-20210371450-A1 PRODUCTION METHOD FOR OLIGONUCLEOTIDES RNGTT, DCLRE1B, PHOSPHO1 THRA 2114/4885THRB 2175/4885SRC 4761/4885
US-20120296074-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE RNGTT, POLM, RNMT THRA 1134/4885THRB 1803/4885SRC 3212/4885
US-20240018180-A1 OLIGONUCLEOTIDE PRODUCTION METHOD RNGTT, NOX4, POLRMT THRA 2919/4885THRB 2294/4885SRC 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.